Breaking News

BioQuiddity and Lee’s Pharmaceutical Enter Agreement

Firms will jointly commercialize two infusion pharmaceuticals in China, Taiwan, Hong Kong and Macau

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BioQuiddity Incorporated, a specialty pharmaceutical company focused on the development and commercialization of large volume ready-to-use infusible pharmaceuticals, and Lee’s Pharmaceutical (HK) Limited, a biopharmaceutical company with over 20 years of operation in Asia, signed a strategic license and supply agreement for the registration and commercialization of BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products in the People’s Republic of China, Taiwan,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters